Services of the district public health social worker in referrals other than the crippled children's program, 1955

Thesis (M.S.)--Boston Universit

Economics and Mental Health

This paper is concerned with the economics of mental health. We argue that mental health economics is like health economics only more so: uncertainty and variation in treatments are greater; the assumption of patient self-interested behavior is more dubious; response to financial incentives such as insurance is exacerbated; the social consequences and external costs of illness are formidable. We elaborate on these statements and consider their implications throughout the chapter. Special characteristics' of mental illness and persons with mental illness are identified and related to observations on institutions paying for and providing mental health services. We show that adverse selection and moral hazard appear to hit mental health markets with special force. We discuss the emergence of new institutions within managed care that address long-standing problems in the sector. Finally, we trace the shifting role of government in this sector of the health economy.

Professional Discourse: An Editorial Comment

McGuire took over as editor from Gerry Gurney. He indicated that starting in Fall 1987, short pieces on topics relevant to the profession may be included in the journal issues. He also proposed some of his own ideas that deviate from rules changes regarding printed materials for prospective athletes and initial eligibility regulations

UNLV Symphony Orchestra: Halloween Spooktacular

Program listing performers and works performe

Cost-Offsets of New Medications for Treatment of Schizophrenia

Broad claims are frequently made that new medications will offset all or part of their costs by reducing other areas of Medicaid spending. In this paper we examine the net impact on spending for new drugs used to treat schizophrenia. We extend research in this area by taking a new approach to identification of spending impacts of new drugs. We specify and estimate models of spending on treatment of schizophrenia using 7 years of Florida Medicaid data. The estimates indicate that use of the new drugs result in net spending increases. This may be due to increased adherence to treatment.